carvedilol has been researched along with Myocardial Ischemia in 62 studies
Myocardial Ischemia: A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a randomized (2:1), double-blinded design study, we studied 25 patients with congestive heart failure (66 +/- 9 years, ejection fraction 30 +/- 7%) before and after 23-week treatment with the beta blocker carvedilol 25 mg twice daily (n = 17) or placebo (n = 8) in addition to standard therapy." | 9.10 | Effect of carvedilol on microcirculatory and glucose metabolic regulation in patients with congestive heart failure secondary to ischemic cardiomyopathy. ( Andreasen, F; Bøttcher, M; Gøtzsche, O; Nielsen, TT; Refsgaard, J, 2002) |
| "We studied effects of beta-adrenoblocker carvedilol vs placebo in 60 patients with chronic cardiac failure (CCF) of functional classes III-IV in a 6-month open randomized trial." | 9.10 | [Endothelial protection in patients with apparent cardiac failure in long-term therapy by carvedilol]. ( Shliakhto, EV; Sitnikova, MIu, 2003) |
| "Carvedilol improved LV regional WMSI in patients with heart failure caused by ischemic heart disease." | 9.09 | Effects of carvedilol on left ventricular regional wall motion in patients with heart failure caused by ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group. ( Doughty, RN; Gamble, G; MacMahon, S; Sharpe, N; Whalley, GA, 2000) |
| "Plasma neurohormones were analyzed for prediction of adverse outcomes and response to treatment in 415 patients with ischemic left ventricular dysfunction randomly assigned to receive carvedilol or placebo." | 9.09 | Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. ( Doughty, R; Espiner, EA; Frampton, C; Ikram, H; Macmahon, S; Nicholls, MG; Richards, AM; Sharpe, N; Yandle, TG, 1999) |
| "The beneficial effects of carvedilol on left-ventricular function and size were maintained for at least a year after the start of treatment, but carvedilol had no effect on exercise performance, symptoms, or episodes of worsening heart failure." | 9.08 | Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group. ( , 1997) |
| "In patients with heart failure of ischemic etiology, 6-month treatment with carvedilol improved left ventricular function and maintained exercise performance at a lower rate-pressure product, but symptoms assessed by functional class were slightly worsened." | 9.08 | Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group. ( , 1995) |
| "In patients with heart failure due to ischemic heart disease, carvedilol therapy for 12 months reduced left ventricular volumes, increased left ventricular ejection fraction and prevented progressive left ventricular dilation." | 9.08 | Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group. ( Doughty, RN; Gamble, G; MacMahon, S; Sharpe, N; Whalley, GA, 1997) |
| "Relative effectiveness of carvedilol and metoprolol succinate has never been compared in patients with heart failure (HF)." | 7.78 | Carvedilol or sustained-release metoprolol for congestive heart failure: a comparative effectiveness analysis. ( Aggarwal, V; Shore, S; Zolty, R, 2012) |
| " The present experiment evaluated the effects of carvedilol, a new beta adrenoreceptor blocker with potent free radical-scavenging activity, on myocardial ischemia and reperfusion injury in a hypercholesterolemic rabbit model." | 7.69 | Carvedilol, a new beta adrenoreceptor blocker and free radical scavenger, attenuates myocardial ischemia-reperfusion injury in hypercholesterolemic rabbits. ( Barone, FC; Christopher, TA; Feuerstein, GZ; Lopez, BL; Ma, XL; Ruffolo, RR; Yue, TL, 1996) |
| "Stevens-Johnson syndrome, related to carvedilol use, has not been previously reported as a serious adverse experience requiring hospitalization." | 7.69 | Stevens-Johnson syndrome associated with carvedilol therapy. ( Cody, RJ; Kowalski, BJ, 1997) |
| " Carvedilol low dose/high dose was shown to be at least as safe and well tolerated as metoprolol low dose/high dose both in younger and elderly patients." | 6.69 | Comparison of safety and efficacy of carvedilol and metoprolol in stable angina pectoris. ( Griffiths, M; Hauf-Zachariou, U; Holtbrügge, W; König, S; Lahiri, A; Pfarr, E; van der Does, R, 1999) |
| "Pretreatment with carvedilol retarded loss of contraction in both axes." | 5.30 | Carvedilol retards sudden loss of contraction during early regional myocardial ischemia in feline hearts. ( Brunvand, H; Grong, K, 1997) |
| "In a randomized (2:1), double-blinded design study, we studied 25 patients with congestive heart failure (66 +/- 9 years, ejection fraction 30 +/- 7%) before and after 23-week treatment with the beta blocker carvedilol 25 mg twice daily (n = 17) or placebo (n = 8) in addition to standard therapy." | 5.10 | Effect of carvedilol on microcirculatory and glucose metabolic regulation in patients with congestive heart failure secondary to ischemic cardiomyopathy. ( Andreasen, F; Bøttcher, M; Gøtzsche, O; Nielsen, TT; Refsgaard, J, 2002) |
| "We studied effects of beta-adrenoblocker carvedilol vs placebo in 60 patients with chronic cardiac failure (CCF) of functional classes III-IV in a 6-month open randomized trial." | 5.10 | [Endothelial protection in patients with apparent cardiac failure in long-term therapy by carvedilol]. ( Shliakhto, EV; Sitnikova, MIu, 2003) |
| "Carvedilol improved LV regional WMSI in patients with heart failure caused by ischemic heart disease." | 5.09 | Effects of carvedilol on left ventricular regional wall motion in patients with heart failure caused by ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group. ( Doughty, RN; Gamble, G; MacMahon, S; Sharpe, N; Whalley, GA, 2000) |
| "Plasma neurohormones were analyzed for prediction of adverse outcomes and response to treatment in 415 patients with ischemic left ventricular dysfunction randomly assigned to receive carvedilol or placebo." | 5.09 | Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. ( Doughty, R; Espiner, EA; Frampton, C; Ikram, H; Macmahon, S; Nicholls, MG; Richards, AM; Sharpe, N; Yandle, TG, 1999) |
| "In patients with heart failure due to ischemic heart disease, carvedilol therapy for 12 months reduced left ventricular volumes, increased left ventricular ejection fraction and prevented progressive left ventricular dilation." | 5.08 | Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group. ( Doughty, RN; Gamble, G; MacMahon, S; Sharpe, N; Whalley, GA, 1997) |
| "In patients with heart failure of ischemic etiology, 6-month treatment with carvedilol improved left ventricular function and maintained exercise performance at a lower rate-pressure product, but symptoms assessed by functional class were slightly worsened." | 5.08 | Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group. ( , 1995) |
| "The beneficial effects of carvedilol on left-ventricular function and size were maintained for at least a year after the start of treatment, but carvedilol had no effect on exercise performance, symptoms, or episodes of worsening heart failure." | 5.08 | Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group. ( , 1997) |
| " The remodeling effect of beta-blockade with carvedilol has been studied in patients with left ventricular dysfunction after myocardial infarction and in patients with chronic heart failure of ischemic etiology." | 4.82 | Cardiac remodeling in coronary artery disease. ( Sharpe, N, 2004) |
| "Relative effectiveness of carvedilol and metoprolol succinate has never been compared in patients with heart failure (HF)." | 3.78 | Carvedilol or sustained-release metoprolol for congestive heart failure: a comparative effectiveness analysis. ( Aggarwal, V; Shore, S; Zolty, R, 2012) |
| "In 102 patients with high risk (52 patients with history of myocardial infarction, 50 patients with history of cerebral stroke within previous 6-48 months) arterial hypertension (AH) we studied clinical efficacy on angiotensin converting enzyme inhibitor (ACEI) lisinopril, calcium antagonist felodipine, and nonselective - -blocker carvedilol in dependence on salt sensitivity of AH." | 3.76 | [Comparative eficacy of antihypertensive therapy in patients with arterial hypertension and various sensitivity to salt]. ( Babkin, AP; Gladkikh, VV; Gulaia, GI; Pershukov, IV, 2010) |
| "Carvedilol, a selective alpha1 and non-selective beta-adrenoceptor antagonist and antioxidant, has been shown to provide significant cardiac protection in animal models of myocardial ischemia." | 3.70 | Comparison of metoprolol and carvedilol pharmacology and cardioprotection in rabbit ischemia and reperfusion model. ( Arch, JR; Cheng, HY; Feuerstein, G; Hieble, JP; Liu, GL; Ma, XL; Ruffolo, RR; Yue, TL, 1998) |
| "Carvedilol, a selective alpha(1) and non-selective beta-adrenoceptor antagonist and antioxidant, has been shown to provide significant cardiac protection in animal models of myocardial ischemia." | 3.70 | Comparison of bisoprolol and carvedilol cardioprotection in a rabbit ischemia and reperfusion model. ( Chen, J; Christopher, TA; Gao, F; Gu, J; Lopez, BL; Lysko, P; Ma, XL; Ohlstein, EH; Ruffolo, RR; Yue, TL, 2000) |
| " The present experiment evaluated the effects of carvedilol, a new beta adrenoreceptor blocker with potent free radical-scavenging activity, on myocardial ischemia and reperfusion injury in a hypercholesterolemic rabbit model." | 3.69 | Carvedilol, a new beta adrenoreceptor blocker and free radical scavenger, attenuates myocardial ischemia-reperfusion injury in hypercholesterolemic rabbits. ( Barone, FC; Christopher, TA; Feuerstein, GZ; Lopez, BL; Ma, XL; Ruffolo, RR; Yue, TL, 1996) |
| "Stevens-Johnson syndrome, related to carvedilol use, has not been previously reported as a serious adverse experience requiring hospitalization." | 3.69 | Stevens-Johnson syndrome associated with carvedilol therapy. ( Cody, RJ; Kowalski, BJ, 1997) |
| " Beta-blocker use at the 2 dosage levels was associated with significant improvement in survival compared with the nonuse of beta blockers (hazard ratios 0." | 2.71 | Effects of beta-blockers on implantable cardioverter defibrillator therapy and survival in the patients with ischemic cardiomyopathy (from the Multicenter Automatic Defibrillator Implantation Trial-II). ( Andrews, M; Brodine, WN; Daubert, JP; Hall, WJ; Hockstad, ES; Lee, JK; McNitt, S; Moss, AJ; Tung, RT; Zareba, W, 2005) |
| "Carvedilol is a nonselective beta-receptor antagonist with vasodilating properties primarily due to selective alpha-1 antagonism." | 2.69 | Effectiveness of three different doses of carvedilol for exertional angina. Carvedilol-Angina Study Group. ( Dennish, G; Ferry, D; Krug-Gourley, S; Lukas, MA; Pickering, E; Smith, LK; Weiss, R, 1998) |
| " Carvedilol low dose/high dose was shown to be at least as safe and well tolerated as metoprolol low dose/high dose both in younger and elderly patients." | 2.69 | Comparison of safety and efficacy of carvedilol and metoprolol in stable angina pectoris. ( Griffiths, M; Hauf-Zachariou, U; Holtbrügge, W; König, S; Lahiri, A; Pfarr, E; van der Does, R, 1999) |
| "Carvedilol is a non-selective β-blocker with α₁-adrenergic receptor antagonism properties." | 2.48 | A critical review of the use of carvedilol in ischemic heart disease. ( Abrencillo, R; Chen-Scarabelli, C; Di Rezze, J; Faggian, G; Gardin, T; Gidwani, UK; Murad, Y; Qureshi, W; Saravolatz, L; Scarabelli, TM; Shieh, WS, 2012) |
| "Carvedilol is a unique cardiovascular drug of multifaceted therapeutic potential." | 2.41 | Carvedilol: molecular and cellular basis for its multifaceted therapeutic potential. ( Cheng, J; Kamiya, K; Kodama, I, 2001) |
| "Carvedilol has been shown to improve exercise tolerance in patients with angina pectoris and reduce the occurrence of episodes of silent myocardial ischaemia." | 2.38 | Carvedilol in ischaemic heart disease. ( Prichard, BN, 1993) |
| "90 patients with chronic form of ischemic heart disease that have been involved in present study along with nitrates, antiplatelet agents and statins received bisoprolol (Group I), carvedilol (Group II) and ivabradine (Group III)." | 1.42 | [The comparative effectiveness of beta-blockers and inhibitors of if-iodium using in patients with stable angina pectoris]. ( Ilashchuk, T; Okipniak, I; Shirokova, S, 2015) |
| "The carvedilol effect was more pronounced in patients with nonischemic dilated cardiomyopathy than in those with ischemic disease." | 1.34 | Effects of carvedilol on plasma levels of pro-inflammatory cytokines in patients with ischemic and nonischemic dilated cardiomyopathy. ( Kurum, T; Tatli, E; Yuksel, M, 2007) |
| "Carvedilol is a beta-adrenoceptor blocker with a vasodilatory action that is more effective for the treatment of congestive heart failure than other beta-blockers." | 1.32 | Beta-adrenoceptor blocker carvedilol provides cardioprotection via an adenosine-dependent mechanism in ischemic canine hearts. ( Asakura, M; Asano, Y; Asanuma, H; Hori, M; Kim, J; Kitakaze, M; Kitamura, S; Liao, Y; Minamino, T; Mori, H; Node, K; Ogai, A; Ogita, H; Sanada, S; Shinozaki, Y; Shintani, Y; Takashima, S; Tomoike, H, 2004) |
| "Carvedilol is an alpha(1)/beta-adrenoceptor antagonist with antioxidant, neuroprotective, cardioprotective and vascularprotective properties, and is used to treat hypertension, myocardial ischaemia and congestive heart failure." | 1.32 | Carvedilol improves energy production during acute global myocardial ischaemia. ( Duarte, AI; Gonçalves, LM; Monteiro, P; Moreno, A; Providência, LA, 2003) |
| "Carvedilol is a beta-adrenoceptor antagonist with multiple actions, which may contribute to superior cardioprotection in heart failure and myocardial infarction." | 1.31 | Differential effects of carvedilol on norepinephrine release in normoxic and ischemic heart. ( Görge, B; Hartmann, F; Katus, HA; Kurz, T; Richardt, D; Richardt, G; Tölg, R, 2000) |
| "Pretreatment with carvedilol retarded loss of contraction in both axes." | 1.30 | Carvedilol retards sudden loss of contraction during early regional myocardial ischemia in feline hearts. ( Brunvand, H; Grong, K, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 20 (32.26) | 18.2507 |
| 2000's | 32 (51.61) | 29.6817 |
| 2010's | 10 (16.13) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dogan, A | 1 |
| Karabacak, M | 1 |
| Tayyar, S | 1 |
| Erdogan, D | 1 |
| Ozaydin, M | 1 |
| Le, DE | 1 |
| Pascotto, M | 1 |
| Leong-Poi, H | 1 |
| Sari, I | 1 |
| Micari, A | 1 |
| Kaul, S | 1 |
| Shirokova, S | 1 |
| Ilashchuk, T | 1 |
| Okipniak, I | 1 |
| de Groote, P | 1 |
| Lamblin, N | 1 |
| Mouquet, F | 1 |
| Bauters, C | 1 |
| Usta, E | 1 |
| Renovanz, M | 1 |
| Mustafi, M | 1 |
| Ziemer, G | 1 |
| Aebert, H | 1 |
| Zakirova, AN | 1 |
| Abdiukova, ER | 1 |
| Babkin, AP | 1 |
| Gladkikh, VV | 1 |
| Pershukov, IV | 1 |
| Gulaia, GI | 1 |
| Ozova, EM | 1 |
| Kiiakbaev, GK | 1 |
| Kobalava, ZhD | 1 |
| Moiseev, VS | 1 |
| Chen-Scarabelli, C | 1 |
| Saravolatz, L | 2 |
| Murad, Y | 1 |
| Shieh, WS | 1 |
| Qureshi, W | 1 |
| Di Rezze, J | 1 |
| Abrencillo, R | 1 |
| Gardin, T | 1 |
| Gidwani, UK | 1 |
| Faggian, G | 1 |
| Scarabelli, TM | 1 |
| Shore, S | 1 |
| Aggarwal, V | 1 |
| Zolty, R | 1 |
| Monami, M | 1 |
| Filippi, L | 1 |
| Ungar, A | 1 |
| Sgrilli, F | 1 |
| Antenore, A | 1 |
| Dicembrini, I | 1 |
| Bagnoli, P | 1 |
| Marchionni, N | 1 |
| Rotella, CM | 1 |
| Mannucci, E | 1 |
| Vasil'ev, AP | 3 |
| Strel'tsova, NN | 3 |
| Gorbunova, TIu | 3 |
| Oliveira, PJ | 1 |
| Rolo, AP | 1 |
| Monteiro, P | 3 |
| Gonçalves, L | 1 |
| Palmeira, CM | 2 |
| Moreno, AJ | 2 |
| Sitnikova, MIu | 1 |
| Shliakhto, EV | 1 |
| Zeng, H | 1 |
| Liu, X | 1 |
| Zhao, H | 1 |
| Duarte, AI | 1 |
| Moreno, A | 1 |
| Gonçalves, LM | 2 |
| Providência, LA | 2 |
| Sharpe, N | 4 |
| Asanuma, H | 1 |
| Minamino, T | 1 |
| Sanada, S | 1 |
| Takashima, S | 1 |
| Ogita, H | 1 |
| Ogai, A | 1 |
| Asakura, M | 1 |
| Liao, Y | 1 |
| Asano, Y | 1 |
| Shintani, Y | 1 |
| Kim, J | 1 |
| Shinozaki, Y | 1 |
| Mori, H | 1 |
| Node, K | 1 |
| Kitamura, S | 1 |
| Tomoike, H | 1 |
| Hori, M | 1 |
| Kitakaze, M | 1 |
| Chi, JL | 1 |
| Sui, XT | 1 |
| Li, SA | 1 |
| Li, J | 1 |
| Hartmann, F | 2 |
| Packer, M | 1 |
| Coats, AJ | 1 |
| Fowler, MB | 1 |
| Krum, H | 1 |
| Mohacsi, P | 1 |
| Rouleau, JL | 1 |
| Tendera, M | 2 |
| Castaigne, A | 1 |
| Anker, SD | 1 |
| Amann-Zalan, I | 1 |
| Hoersch, S | 1 |
| Katus, HA | 2 |
| Palloshi, A | 1 |
| Fragasso, G | 1 |
| Silipigni, C | 1 |
| Locatelli, M | 1 |
| Cristell, N | 1 |
| Pala, MG | 1 |
| Alfieri, O | 1 |
| Margonato, A | 1 |
| Carreira, R | 1 |
| Duarte, A | 1 |
| Santos, MS | 1 |
| Rego, AC | 1 |
| Oliveira, CR | 1 |
| Cinquegrana, G | 1 |
| D'Aniello, L | 1 |
| Landi, M | 1 |
| Spinelli, L | 1 |
| Grande, G | 1 |
| De Prisco, F | 1 |
| Petretta, M | 1 |
| Green, P | 1 |
| Anshelevich, M | 1 |
| Talreja, A | 1 |
| Burcham, JL | 1 |
| Ravi, SM | 1 |
| Shirani, J | 1 |
| Le Jemtel, TH | 1 |
| Gaibazzi, N | 1 |
| Brodine, WN | 1 |
| Tung, RT | 1 |
| Lee, JK | 1 |
| Hockstad, ES | 1 |
| Moss, AJ | 1 |
| Zareba, W | 1 |
| Hall, WJ | 1 |
| Andrews, M | 1 |
| McNitt, S | 1 |
| Daubert, JP | 1 |
| Kaandorp, TA | 1 |
| Lamb, HJ | 1 |
| Bax, JJ | 1 |
| Boersma, E | 1 |
| Viergever, EP | 1 |
| van der Wall, EE | 1 |
| de Roos, A | 1 |
| Paraskevaidis, IA | 1 |
| Tsiapras, D | 1 |
| Karavolias, G | 1 |
| Adamopoulos, S | 1 |
| Dodouras, T | 1 |
| Cokkinos, P | 1 |
| Kremastinos, DT | 1 |
| Igarashi, N | 1 |
| Nozawa, T | 1 |
| Fujii, N | 1 |
| Suzuki, T | 1 |
| Matsuki, A | 1 |
| Nakadate, T | 1 |
| Igawa, A | 1 |
| Inoue, H | 1 |
| Kurum, T | 1 |
| Tatli, E | 1 |
| Yuksel, M | 1 |
| Gandhi, PS | 1 |
| Goyal, RK | 1 |
| Jain, AR | 1 |
| Mallya, BS | 1 |
| Gupta, VM | 1 |
| Shah, DS | 1 |
| Trivedi, BR | 1 |
| Shastri, NA | 1 |
| Mehta, CB | 1 |
| Jain, KA | 1 |
| Bhavasar, NS | 1 |
| Shah, UJ | 1 |
| Fox, K | 1 |
| Borer, JS | 1 |
| Camm, AJ | 1 |
| Danchin, N | 1 |
| Ferrari, R | 1 |
| Lopez Sendon, JL | 1 |
| Steg, PG | 1 |
| Tardif, JC | 1 |
| Tavazzi, L | 1 |
| González Maqueda, I | 1 |
| Taylor, SH | 1 |
| Storstein, L | 1 |
| Prichard, BN | 1 |
| Ma, XL | 4 |
| Yue, TL | 4 |
| Lopez, BL | 2 |
| Barone, FC | 1 |
| Christopher, TA | 2 |
| Ruffolo, RR | 4 |
| Feuerstein, GZ | 2 |
| Quaife, RA | 1 |
| Gilbert, EM | 2 |
| Christian, PE | 1 |
| Datz, FL | 1 |
| Mealey, PC | 1 |
| Volkman, K | 1 |
| Olsen, SL | 1 |
| Bristow, MR | 2 |
| Basu, S | 1 |
| Senior, R | 1 |
| Raftery, EB | 1 |
| Lahiri, A | 2 |
| Doughty, RN | 2 |
| Whalley, GA | 2 |
| Gamble, G | 2 |
| MacMahon, S | 3 |
| Abraham, WT | 1 |
| Yoshikawa, T | 1 |
| White, M | 1 |
| Hattler, BG | 1 |
| Crisman, TS | 1 |
| Lowes, BD | 1 |
| Robertson, AD | 1 |
| Larrabee, P | 1 |
| Brunvand, H | 1 |
| Grong, K | 1 |
| Kowalski, BJ | 1 |
| Cody, RJ | 1 |
| Wang, X | 1 |
| Romanic, AM | 1 |
| Liu, GL | 2 |
| Louden, C | 1 |
| Gu, JL | 1 |
| Kumar, S | 1 |
| Poste, G | 1 |
| Feuerstein, G | 1 |
| Cheng, HY | 1 |
| Hieble, JP | 1 |
| Arch, JR | 1 |
| Khandoudi, N | 1 |
| Percevault-Albadine, J | 1 |
| Bril, A | 1 |
| Weiss, R | 1 |
| Ferry, D | 1 |
| Pickering, E | 1 |
| Smith, LK | 1 |
| Dennish, G | 1 |
| Krug-Gourley, S | 1 |
| Lukas, MA | 1 |
| Santos, DJ | 1 |
| Richards, AM | 1 |
| Doughty, R | 1 |
| Nicholls, MG | 1 |
| Ikram, H | 1 |
| Espiner, EA | 1 |
| Frampton, C | 1 |
| Yandle, TG | 1 |
| van der Does, R | 1 |
| Hauf-Zachariou, U | 1 |
| Pfarr, E | 1 |
| Holtbrügge, W | 1 |
| König, S | 1 |
| Griffiths, M | 1 |
| Cohn, LJ | 1 |
| Kurz, T | 1 |
| Richardt, D | 1 |
| Görge, B | 1 |
| Tölg, R | 1 |
| Richardt, G | 1 |
| Dickerson, LM | 1 |
| Carek, PJ | 1 |
| Gao, F | 1 |
| Chen, J | 1 |
| Gu, J | 1 |
| Lysko, P | 1 |
| Ohlstein, EH | 1 |
| Horio, T | 1 |
| Ito, S | 1 |
| Aoyama, M | 1 |
| Takeda, Y | 1 |
| Suzumura, H | 1 |
| Nakata, K | 1 |
| Yamada, Y | 1 |
| Suzuki, S | 1 |
| Fukutomi, T | 1 |
| Itoh, M | 1 |
| Cheng, J | 1 |
| Kamiya, K | 1 |
| Kodama, I | 1 |
| Dubova, TV | 1 |
| Bøttcher, M | 1 |
| Refsgaard, J | 1 |
| Gøtzsche, O | 1 |
| Andreasen, F | 1 |
| Nielsen, TT | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Single Centre, Retrospective Cohort Study on Post Analysis on the Link Between the Clinical Heart Rate and Outcomes During PCI[NCT02351674] | 15,000 participants (Anticipated) | Observational | 2015-01-31 | Not yet recruiting | |||
| Heart Rate Lowering Efficacy and Respiratory Safety of Ivabradine in Patients With Obstructive Airway Disease[NCT01365286] | Phase 4 | 40 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| Bisoprolol Plasma Residual Concentrations for the Optimization of Drug Management in Heart Failure With Mild to Reduced Ejection Fraction[NCT03644446] | 81 participants (Anticipated) | Observational [Patient Registry] | 2017-11-02 | Recruiting | |||
| A Multicenter,Randomized, Double Blind, Double Dummy, Parallel Group Study to Compare Effects of Coreg CR and Coreg IR on Left Ventricular End Systolic Volume Index in Subjects With Stable Chronic Heart Failure[NCT00323037] | Phase 3 | 318 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
| Collaborative Systematic Overview of Randomised Controlled Trials of Beta-Blockers in the Treatment of Heart Failure[NCT00832442] | 18,240 participants (Anticipated) | Observational | 2008-08-31 | Enrolling by invitation | |||
| A Multicenter, Placebo-Controlled, 8-Month Study of the Effect of Twice Daily Carvedilol in Children With Congestive Heart Failure Due to Systemic Ventricular Systolic Dysfunction[NCT00052026] | Phase 3 | 161 participants (Actual) | Interventional | 2000-05-31 | Completed | ||
| Reverse Remodeling is Associated With Hemodynamic Improvement and Stabilization in Outpatients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan: an Echocardiographic Study[NCT04397302] | 652 participants (Actual) | Observational [Patient Registry] | 2019-01-13 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | -0.88 |
| Carvedilol Controlled Release | -0.86 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | 24.00 |
| Carvedilol Controlled Release | 53.37 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | -0.20 |
| Carvedilol Controlled Release | -0.45 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | -0.33 |
| Carvedilol Controlled Release | -0.36 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | -0.76 |
| Carvedilol Controlled Release | -0.83 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | .08 |
| Carvedilol Controlled Release | .05 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | .08 |
| Carvedilol Controlled Release | .08 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | -36.61 |
| Carvedilol Controlled Release | -42.22 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | -18.29 |
| Carvedilol Controlled Release | -20.57 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | -36.61 |
| Carvedilol Controlled Release | -43.00 |
Maintenance Visit 3 minus Baseline. Maintenance Visit 3 occurred 24 weeks after entry into the maintenance period. The maintenance period started after completion of a titration period of variable duration. (NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | mL/m^2 (Mean) |
|---|---|
| Coreg Immediate Release | -18.36 |
| Coreg Controlled Release | -20.81 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | 9.5 |
| Carvedilol Controlled Release | -9.29 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | .07 |
| Carvedilol Controlled Release | .05 |
SAEs experienced (NCT00323037)
Timeframe: 24 weeks after entry into the maintenance phase (after unblinding)
| Intervention | number of SAEs (Number) |
|---|---|
| Carvedilol Immediate Release | 40 |
| Carvedilol Controlled Release | 35 |
(NCT00323037)
Timeframe: Up to 32 weeks (titration and maintenance phases)
| Intervention | subjects in each treatment group (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Study Entry (10mg Coreg CR, 3.125mg Coreg IR) | Maintenance Entry (10mg Coreg CR, 3.125mg Coreg IR) | End of Study (10mg Coreg CR, 3.125mg Coreg IR) | Study Entry (20mg Coreg CR, 6.25mg Coreg IR) | Maintenance Entry (20mg Coreg CR, 6.25mg Coreg IR) | End of Study (20mg Coreg CR, 6.25mg Coreg IR) | Study Entry (40mg Coreg CR, 12.5mg Coreg IR) | Maintenance Entry (40mg Coreg CR, 12.5mg Coreg IR) | End of Study (40mg Coreg CR, 12.5mg Coreg IR) | Study Entry (80mg Coreg CR, 25mg Coreg IR) | Maintenance Entry (80mg Coreg CR, 25mg Coreg IR) | End of Study (80mg Coreg CR, 25mg Coreg IR) | |
| Carvedilol Controlled Release | 83 | 0 | 4 | 39 | 9 | 16 | 27 | 16 | 22 | 4 | 114 | 111 |
| Carvedilol Immediate Release | 79 | 0 | 7 | 61 | 13 | 16 | 21 | 12 | 21 | 4 | 116 | 121 |
(NCT00323037)
Timeframe: Up to 32 weeks (titration and maintenance phases)
| Intervention | participants in each treatment group (Number) | ||
|---|---|---|---|
| Hospitalization for Heart Failure | Hospitalization Due to Any Cause | Hospitalization or Death | |
| Carvedilol Controlled Release | 6 | 29 | 29 |
| Carvedilol Immediate Release | 6 | 31 | 32 |
7 reviews available for carvedilol and Myocardial Ischemia
| Article | Year |
|---|---|
A critical review of the use of carvedilol in ischemic heart disease.
Topics: Adrenergic beta-Antagonists; Angina, Stable; Animals; Anti-Arrhythmia Agents; Antioxidants; Arrhythm | 2012 |
Further data on beta-blockers and cancer risk: observational study and meta-analysis of randomized clinical trials.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Benzopyrans; Bisoprolol; Carbazoles; Carvedilol; Diabet | 2013 |
Cardiac remodeling in coronary artery disease.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Echocardiography; Heart Failure; Humans; Myocar | 2004 |
Resting heart rate in cardiovascular disease.
Topics: Adrenergic beta-Antagonists; Animals; Arrhythmias, Cardiac; Calcium Channel Blockers; Carbazoles; Ca | 2007 |
Resting heart rate in cardiovascular disease.
Topics: Adrenergic beta-Antagonists; Animals; Arrhythmias, Cardiac; Calcium Channel Blockers; Carbazoles; Ca | 2007 |
Resting heart rate in cardiovascular disease.
Topics: Adrenergic beta-Antagonists; Animals; Arrhythmias, Cardiac; Calcium Channel Blockers; Carbazoles; Ca | 2007 |
Resting heart rate in cardiovascular disease.
Topics: Adrenergic beta-Antagonists; Animals; Arrhythmias, Cardiac; Calcium Channel Blockers; Carbazoles; Ca | 2007 |
Carvedilol in ischaemic heart disease.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Exercise Tolerance; Free Radical Scavengers; He | 1993 |
Ischemic heart disease: the role of mitochondria--carvedilol prevents lipid peroxidation of mitochondrial membranes.
Topics: Animals; Antioxidants; Calcium; Carbazoles; Carvedilol; Cell Membrane Permeability; Energy Metabolis | 1998 |
Carvedilol: molecular and cellular basis for its multifaceted therapeutic potential.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Antioxi | 2001 |
28 trials available for carvedilol and Myocardial Ischemia
| Article | Year |
|---|---|
Comparison of the effects of carvedilol and nebivolol on diastolic functions of the left ventricle in patients with non-ischemic heart failure.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Agonists; Carbazoles; Carvedilol | 2014 |
[Effect of beta-adrenoblockers on remodeling of myocardium and adhesive function of endothelium in patients with ischemic heart disease, complicated with chronic heart failure and atrial fibrillation].
Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Carbazoles; Carvedilol; Cell Adhesion Molecu | 2010 |
[Effect of carvedilol and metoprolol R administered with or without atorvastatin on elastic properties of vascular wall and parameters of inflammation in patients with chronic heart failure of ischemic origin].
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Aged; Anticholesteremic Agents; Arterioles; Atorvasta | 2011 |
Further data on beta-blockers and cancer risk: observational study and meta-analysis of randomized clinical trials.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Benzopyrans; Bisoprolol; Carbazoles; Carvedilol; Diabet | 2013 |
[Status of microcirculation and cardiodynamics in ischemic heart disease patients with decreased left ventricular fraction and their response to carvedilol].
Topics: Carbazoles; Carvedilol; Cross-Over Studies; Heart; Humans; Microcirculation; Myocardial Ischemia; Pr | 2002 |
[Contribution of antioxidant properties of carvedilol in its effect on cardiac remodeling in patients with ischemic heart disease with incipient heart failure].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Antioxida | 2003 |
[Endothelial protection in patients with apparent cardiac failure in long-term therapy by carvedilol].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; Drug Therapy, | 2003 |
[Clinical observation of 41 cases of senile ischemic heart disease treated by losarton, carvadilol and Shenmai Injection].
Topics: Aged; Carbazoles; Carvedilol; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Humans; Losa | 2003 |
Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial.
Topics: Adrenergic beta-Antagonists; Aged; Biomarkers; Blood Pressure; Carbazoles; Cardiovascular Agents; Ca | 2004 |
Early detection by the Tei index of carvedilol-induced improved left ventricular function in patients with heart failure.
Topics: Adrenergic alpha-Antagonists; Aged; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Diastole; Echoc | 2004 |
Effects of different degrees of sympathetic antagonism on cytokine network in patients with ischemic dilated cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Echocardiography; Fema | 2005 |
Effects of beta-blockers on implantable cardioverter defibrillator therapy and survival in the patients with ischemic cardiomyopathy (from the Multicenter Automatic Defibrillator Implantation Trial-II).
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Carbazoles; Carvedilol; Defibrillators, Implantable; Fe | 2005 |
The effect of carvedilol therapy on myocardial functional reserve in patients with advanced heart failure caused by nonischemic dilated cardiomyopathy.
Topics: Adult; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Female; Heart; Heart Failure; Humans; Male; | 2006 |
Beneficial effects of carvedilol as a concomitant therapy to angiotensin-converting enzyme inhibitor in patients with ischemic left ventricular systolic dysfunction.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; | 2007 |
[Efficiency of taliton in treatment of ischemic cardiomyopathy].
Topics: Adult; Aged; Antihypertensive Agents; Carbazoles; Cardiomyopathies; Carvedilol; Humans; Male; Middle | 2007 |
Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Double-Blind Method; Echocardiography; Ex | 1995 |
Adrenoreceptors, endothelial function, and lipid profile: effects of atenolol, doxazosin, and carvedilol.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Carbazoles; Carvedilol; Cholesterol; | 1994 |
Effects of carvedilol on systolic and diastolic left ventricular performance in idiopathic dilated cardiomyopathy or ischemic cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiac Catheterization; Cardiac Volume; Cardiomyopathy, Di | 1996 |
The association between cardiac events and myocardial ischaemia following thrombolysis in acute myocardial infarction and the impact of carvedilol.
Topics: Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Confidence Intervals; Coronary Angiography; | 1996 |
Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group.
Topics: Adrenergic beta-Antagonists; Aged; Australia; Carbazoles; Carvedilol; Double-Blind Method; Exercise | 1997 |
Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group.
Topics: Adrenergic beta-Antagonists; Aged; Australia; Carbazoles; Carvedilol; Double-Blind Method; Exercise | 1997 |
Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group.
Topics: Adrenergic beta-Antagonists; Aged; Australia; Carbazoles; Carvedilol; Double-Blind Method; Exercise | 1997 |
Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group.
Topics: Adrenergic beta-Antagonists; Aged; Australia; Carbazoles; Carvedilol; Double-Blind Method; Exercise | 1997 |
Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group.
Topics: Adrenergic beta-Antagonists; Aged; Australia; Carbazoles; Carvedilol; Double-Blind Method; Exercise | 1997 |
Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group.
Topics: Adrenergic beta-Antagonists; Aged; Australia; Carbazoles; Carvedilol; Double-Blind Method; Exercise | 1997 |
Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group.
Topics: Adrenergic beta-Antagonists; Aged; Australia; Carbazoles; Carvedilol; Double-Blind Method; Exercise | 1997 |
Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group.
Topics: Adrenergic beta-Antagonists; Aged; Australia; Carbazoles; Carvedilol; Double-Blind Method; Exercise | 1997 |
Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group.
Topics: Adrenergic beta-Antagonists; Aged; Australia; Carbazoles; Carvedilol; Double-Blind Method; Exercise | 1997 |
Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Double-Blind Method; Echocardiography; Fe | 1997 |
Second- and third-generation beta-blocking drugs in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Cardiac Output, Low; Cardiomyopathy, Dilated; | 1997 |
Effectiveness of three different doses of carvedilol for exertional angina. Carvedilol-Angina Study Group.
Topics: Aged; Angina Pectoris; Carbazoles; Carvedilol; Cross-Over Studies; Double-Blind Method; Exercise Tes | 1998 |
Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group.
Topics: Arginine Vasopressin; Atrial Natriuretic Factor; Carbazoles; Carvedilol; Double-Blind Method; Heart | 1999 |
Comparison of safety and efficacy of carvedilol and metoprolol in stable angina pectoris.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Age Factors; Aged; Angina Pectoris; Antio | 1999 |
Effects of carvedilol on left ventricular regional wall motion in patients with heart failure caused by ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; | 2000 |
[Clinical and hemodynamic effects of anaprilin and carvedilol in patients with coronary heart disease].
Topics: Carbazoles; Carvedilol; Cross-Over Studies; Hemodynamics; Humans; Myocardial Ischemia; Propanolamine | 2001 |
Effect of carvedilol on microcirculatory and glucose metabolic regulation in patients with congestive heart failure secondary to ischemic cardiomyopathy.
Topics: Aged; Analysis of Variance; Blood Glucose; Carbazoles; Carvedilol; Catecholamines; Coronary Vessels; | 2002 |
28 other studies available for carvedilol and Myocardial Ischemia
| Article | Year |
|---|---|
Anti-inflammatory and pro-angiogenic effects of beta blockers in a canine model of chronic ischemic cardiomyopathy: comparison between carvedilol and metoprolol.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Dogs; Echocardiography; Heart; Immunoh | 2013 |
[The comparative effectiveness of beta-blockers and inhibitors of if-iodium using in patients with stable angina pectoris].
Topics: Adrenergic beta-Antagonists; Angina, Stable; Benzazepines; Bisoprolol; Carbazoles; Carvedilol; Elect | 2015 |
No gender survival difference in a population of patients with chronic heart failure related to left ventricular systolic dysfunction and receiving optimal medical therapy.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Cardiomyopathies; | 2008 |
Human cardiac tissue in a microperfusion chamber simulating extracorporeal circulation--ischemia and apoptosis studies.
Topics: Adrenergic beta-Antagonists; Analysis of Variance; Apoptosis; Biopsy; Calcium; Carbazoles; Carvedilo | 2010 |
[Comparative eficacy of antihypertensive therapy in patients with arterial hypertension and various sensitivity to salt].
Topics: Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Carbazoles; Carvedil | 2010 |
Carvedilol or sustained-release metoprolol for congestive heart failure: a comparative effectiveness analysis.
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiomyopathies; Carvedilol; Cohort Studies; Delayed-Actio | 2012 |
Impact of carvedilol on the mitochondrial damage induced by hypoxanthine and xantine oxidase--what role in myocardial ischemia and reperfusion?
Topics: Animals; Antioxidants; Carbazoles; Carvedilol; Hypoxanthine; Male; Mitochondria, Heart; Myocardial I | 2002 |
Effects of carvedilol on cardiomyocyte apoptosis and gene expression in vivo after ischemia-reperfusion in rats.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Apoptosis; bcl-2-Associated X Pr | 2003 |
Carvedilol improves energy production during acute global myocardial ischaemia.
Topics: Animals; Carbazoles; Carvedilol; Energy Metabolism; Membrane Potentials; Mitochondria, Heart; Myocar | 2003 |
Beta-adrenoceptor blocker carvedilol provides cardioprotection via an adenosine-dependent mechanism in ischemic canine hearts.
Topics: 5'-Nucleotidase; Adenosine; Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Cells, Cul | 2004 |
Carvedilol protects ischemic cardiac mitochondria by preventing oxidative stress.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Mitochondria, Heart; Myocardial Ischem | 2004 |
Long-term effects of carvedilol or metoprolol on left ventricular function in ischemic and nonischemic cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Cardiomyopathy, Dilated; Ca | 2005 |
Early detection by the Tei index of carvedilol-induced improved left ventricular function in patients with heart failure.
Topics: Adrenergic alpha-Antagonists; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Diastole; Echocardiog | 2005 |
Prediction of beneficial effect of beta blocker treatment in severe ischaemic cardiomyopathy: assessment of global left ventricular ejection fraction using dobutamine stress cardiovascular magnetic resonance.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Dobutamine; Feasibili | 2005 |
Influence of beta-adrenoceptor blockade on the myocardial accumulation of fatty acid tracer and its intracellular metabolism in the heart after ischemia-reperfusion injury.
Topics: Adrenergic beta-Antagonists; Animals; Autoradiography; Carbazoles; Carvedilol; Fatty Acids; Iodobenz | 2006 |
Effects of carvedilol on plasma levels of pro-inflammatory cytokines in patients with ischemic and nonischemic dilated cardiomyopathy.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Blood Pressure; Carbazoles; | 2007 |
Carvedilol--a wide therapeutic potential in cardiovascular syndromes. Introduction.
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Carbazoles; Carvedilol; Free Radical Scavengers; | 1993 |
Carvedilol, a new beta adrenoreceptor blocker and free radical scavenger, attenuates myocardial ischemia-reperfusion injury in hypercholesterolemic rabbits.
Topics: Adrenergic beta-Antagonists; Animals; Blood Pressure; Carbazoles; Carvedilol; Endothelium, Vascular; | 1996 |
Carvedilol retards sudden loss of contraction during early regional myocardial ischemia in feline hearts.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Cardiac Output; Carvedilol; Cats; Coronary Circula | 1997 |
Stevens-Johnson syndrome associated with carvedilol therapy.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Humans; Male; Myocardial Ischemia; Propan | 1997 |
Possible involvement of stress-activated protein kinase signaling pathway and Fas receptor expression in prevention of ischemia/reperfusion-induced cardiomyocyte apoptosis by carvedilol.
Topics: Adrenergic beta-Antagonists; Animals; Apoptosis; Carbazoles; Carvedilol; DNA Fragmentation; Down-Reg | 1998 |
Comparison of metoprolol and carvedilol pharmacology and cardioprotection in rabbit ischemia and reperfusion model.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Antioxidants; Blood Pressure; Ca | 1998 |
Comparative effects of carvedilol and metoprolol on cardiac ischemia-reperfusion injury.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; L-La | 1998 |
Carvedilol.
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Heart Failure; Hemodyn | 1999 |
Differential effects of carvedilol on norepinephrine release in normoxic and ischemic heart.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Heart; Male; Myocardial Ischemia; Myoc | 2000 |
Are there differences between vasodilating and nonvasodilating beta-blockers in patients with heart failure? Do patients with ischemic heart disease benefit to the same degree?
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Female; Heart Failure; Hospitalization; Humans; | 2000 |
Comparison of bisoprolol and carvedilol cardioprotection in a rabbit ischemia and reperfusion model.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Antioxidants; Bisoprolol; Carbazoles | 2000 |
Effect of carvedilol on atrioventricular conduction in the ischemic heart.
Topics: Action Potentials; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Bundle of His | 2001 |